Varenicline
Chantix
Nicotinic Partial AgonistGeneric availableTDM data
Varenicline binds with high affinity and selectivity at the alpha4-beta2 neuronal nicotinic acetylcholine receptor, where it acts as a partial agonist — providing modest dopamine release to reduce craving and withdrawal, while simultaneously blocking nicotine from binding and reducing the reinforcing effects of smoking.
Compare Varenicline →FDA-Approved Indications
- Aid to smoking cessation treatment in adults
What Sets This Drug Apart
- Most effective single-agent pharmacotherapy for smoking cessation — NNT ~8-10 vs placebo at 6 months
- Nausea in ~30% of patients — the most common side effect and primary reason for discontinuation
- Minimal drug-drug interaction potential — 92% renally eliminated unchanged, no CYP involvement
- FDA removed neuropsychiatric boxed warning in 2016 after EAGLES trial (N=8144) showed no signal vs NRT or placebo
- Unique mechanism — partial agonist at alpha4beta2 nAChR provides craving relief while blocking nicotine reward